Document is current
Any future updates will be listed below
-
Authors
Mattheisen, Manuel https://orcid.org/0000-0002-8442-493X
Grove, Jakob https://orcid.org/0000-0003-2284-5744
Als, Thomas D. https://orcid.org/0000-0002-2963-1928
Martin, Joanna
Voloudakis, Georgios https://orcid.org/0000-0002-5729-632X
Meier, Sandra
Demontis, Ditte https://orcid.org/0000-0001-9124-2766
Bendl, Jaroslav https://orcid.org/0000-0001-9989-2720
Walters, Raymond https://orcid.org/0000-0001-8422-6530
Carey, Caitlin E.
Rosengren, Anders https://orcid.org/0000-0002-6682-1288
Strom, Nora I. https://orcid.org/0000-0002-5261-8852
Hauberg, Mads Engel https://orcid.org/0000-0003-4873-2764
Zeng, Biao
Hoffman, Gabriel https://orcid.org/0000-0002-0957-0224
Zhang, Wen
Bybjerg-Grauholm, Jonas https://orcid.org/0000-0003-1705-4008
Bækvad-Hansen, Marie
Agerbo, Esben https://orcid.org/0000-0002-2849-524X
Cormand, Bru https://orcid.org/0000-0001-5318-4382
Nordentoft, Merete
Werge, Thomas https://orcid.org/0000-0003-1829-0766
Mors, Ole
Hougaard, David M. https://orcid.org/0000-0001-5928-3517
Buxbaum, Joseph D. https://orcid.org/0000-0001-8898-8313
Faraone, Stephen V.
Franke, Barbara https://orcid.org/0000-0003-4375-6572
Dalsgaard, Søren https://orcid.org/0000-0003-4659-0969
Mortensen, Preben B.
Robinson, Elise B.
Roussos, Panos https://orcid.org/0000-0002-4640-6239
Neale, Benjamin M. https://orcid.org/0000-0003-1513-6077
Daly, Mark J.
Børglum, Anders D. https://orcid.org/0000-0001-8627-7219
- License Information
-
More Information
Article History
Received: 1 June 2021
Accepted: 20 June 2022
First Online: 26 September 2022
Competing interests
: B.F. has received educational speaking fees from Medice. In the past year, S.V.F. has received income, potential income, travel expenses, continuing education support and/or research support from Takeda, OnDosis, Tris, Otsuka, Arbor, Ironshore, Rhodes, Akili Interactive Labs, Sunovion, Supernus and Genomind. With his institution, S.V.F. has US patent US20130217707 A1 for the use of sodium–hydrogen exchange inhibitors in the treatment of ADHD. S.V.F. also receives royalties from books published by Guilford Press (<i>Straight Talk about Your Child’s Mental Health</i>), Oxford University Press (<i>Schizophrenia: The Facts</i>) and Elsevier (<i>ADHD: Non-Pharmacologic Interventions</i>). S.V.F. is Program Director of . B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora (formerly Neumora) and consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen. M.J.D. is a founder of Maze Therapeutics and is on the Scientific Advisory Board of RBNC Therapeutics. The other authors declare no competing interests.
